This document summarises the Life Saving Drugs Program Expert Panel's consideration of BioMarin's application to include cerliponase alfa (Brineura®) on the Life Saving Drugs Program for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
The document contains:
- Overview
- Background
- PBAC consideration
- Consumer input
- LSDP Expert Panel consideration
- Treatment guidelines
- Context
- Sponsor’s comment.
Life Saving Drugs Program – Cerliponase alfa (Brineura®) outcome statement
About this resource
Publication date:
Publication type:
Report
Audience:
General public
Language:
English